Key facts
- EvolutionaryScale’s last known valuation is $1.0B.
- It has raised $182.0M; the latest was Seed Round ($142.0M) in Jun 2024.
- Notable investors include Lux Capital, Quiet Capital, NVentures (Santa Clara), Nat Friedman, Amazon Web Services — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for EvolutionaryScale
- ·The full record, as it builds
Funding rounds
No funding rounds for EvolutionaryScale are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EvolutionaryScale
Developer of biology artificial intelligence models designed for the frontiers of scientific discovery. The company's technology predicts protein structures by integrating biological data from deoxyribonucleic acid sequences, gene expression and epigenetic states, enabling researchers to apply large language models to design ribonucleic acid-based drug therapies.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 41
- Website
- evolutionaryscale.ai/
- Ownership
- Privately Held (backing)
EvolutionaryScale doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EvolutionaryScale shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EvolutionaryScale in its N-PORT filings yet. We sweep new filings monthly.